Polyrizon Ltd. (PLRZ) announced that it has submitted a Pre-Request for Designation to the U.S. FDA for its PL-16 Viral Blocker, a non-pharmacological intranasal product designed to reduce exposure to airborne respiratory viruses, including influenza and cold viruses.
The FDA submission initiates a formal dialogue with the agency on the appropriate regulatory pathway for PL-16.
Seasonal respiratory infections remain a significant public health challenge, causing millions of cases and tens of thousands of hospitalizations each year. Current preventive options are largely pharmaceutical, symptom-focused, or vaccine-dependent, leaving a gap for drug-free, locally acting solutions.
PL-16 is a metered-dose intranasal spray containing a biodegradable hydrogel formulation. Upon application, it forms a thin, muco-adhesive layer on the nasal mucosa, acting as a physical barrier to mechanically block viral particles from contacting epithelial tissue.
Preclinical studies demonstrated over 90% protection of cells against influenza A (H1N1) and human coronavirus 229E, confirming its barrier-based mechanism.
Polyrizon's broader pipeline includes PL-14 Allergy Blocker, which uses a similar hydrogel technology to reduce exposure to airborne allergens. Together, these programs reflect the company's strategy to develop scalable, drug-free nasal technologies for multiple exposure-driven respiratory indications.
PLRZ is currently trading at $9.90, down 2.08%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.